Insider Cluster (2 insiders) ·Filed Jun 18, 2026

MLYS

Mineralys Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $310K total
Actionable Insight • Neutral

The insider sales are routine and non-informative given the trivial dollar amount and pattern of exercise-and-sell. No bearish read-through. Monitor upcoming clinical trial readouts for MLYS's pipeline as the primary catalyst.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
MLYS ▲ +17.54% at T+60d
NEUTRAL call ✓ call won +17.54% · α vs SPY +15.65% · entry $24.63 → $28.95
Entry anchored
Jun 17, 03:59 PM ET
via exchange tick
T+1d
+3.00%
call +3.00% · α +3.32%
$25.37
settled 4mo ago
T+5d
+6.94%
call +6.94% · α +8.61%
$26.34
settled 3mo ago
T+20d
+9.95%
call +9.95% · α +9.41%
$27.08
settled 3mo ago
T+60d
+17.54%
call +17.54% · α +15.65%
$28.95
settled 18d ago

Price Chart

Loading chart...

Executive Summary

Two insiders at Mineralys Therapeutics (MLYS) sold a combined $310K in open-market transactions over a 7-day window. The dollar amount is trivial relative to the $2.0B market cap (0.0155%), and the sales follow option exercises, indicating routine tax/vesting-related liquidity rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$310.0K
Insiders
2

Key Facts

  • CMO Rodman David Malcom sold 9,900 shares at $23.81 on June 15, 2026, for $235K
  • Director Daphne Karydas sold 3,000 shares at $25.00 on June 17, 2026, for $75K
  • Total open-market sales of $310K represent 0.0155% of MLYS's $2.0B market cap
  • Both sales were preceded by option exercises at nominal or low strike prices, consistent with tax withholding or diversification

Financial Impact

Total insider sales of $310K are immaterial at 0.0155% of market cap; no financial impact on the company.

insider selling

Risk Factors

  • No material risk identified from this cluster; the sales are liquidity-driven and not indicative of fundamental deterioration

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MLYS-1781745507906
22 reports for MLYS
Performance horizon
67% Hit rate 4 of 6 directional calls best @ T+20▲ +20.97%Jun 11, 2026
Filters
Rows
Reports for MLYS — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
3
NEUTRAL ★ 2/10
$26.09 $28.20▲ +8.09%▲ +9.83%$23.56 (−9.70%)
Jul 23, 2026
10w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.71 $25.65▼ −3.97%▼ −7.59%$23.56 (−11.79%)
Jul 21, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.52 $26.61▼ −3.31%▼ −5.87%$23.56 (−14.39%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.08 $26.09▼ −3.66%▼ −7.27%$23.56 (−13.00%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.89 $26.35▼ −2.01%▲ +0.18%$23.56 (−12.38%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.88 $26.71▼ −0.63%▼ −0.35%$23.56 (−12.35%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 17, 2026
15w ago
144
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$23.94 $28.96▲ +20.97%▲ +19.08%$23.56 (−1.59%)
Jun 3, 2026
17w ago
8-K
MIXED ★ 7/10
$25.06 $27.69▲ +10.49%▲ +11.49%$23.56 (−5.99%)
Showing 10 of 22

US Market Status

Market Open — Closes in 3h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 18, 2026